SkinVive by Juvederm in Myeongdong Seoul — Hyaluronic Acid Skin Quality Treatment

Hyaluronic Acid Microdroplet Technology and Dermal Hydration

SkinVive by Juvederm (JUVÉDERM SKINVIVE, Allergan Aesthetics) contains a modified hyaluronic acid gel formulated specifically for intradermal injection as microdroplets. Unlike traditional HA fillers that use highly cross-linked HA for volumizing and structural support, SkinVive uses a lower cross-linking density optimized for dermal integration and water absorption. Each microdroplet creates a microscopic reservoir that attracts and binds water molecules within the extracellular matrix of the dermis, increasing tissue hydration from within. This mechanism is distinct from topical hyaluronic acid products that only hydrate the stratum corneum (outermost skin layer) — SkinVive delivers HA directly to the living dermis where it can interact with native glycosaminoglycans and proteoglycans. Niforos et al. (2023) demonstrated in the pivotal Phase 3 SKIN clinical trial that SkinVive produced statistically significant improvement in Patient Skin Quality Assessment (PSQA) scores for cheek smoothness at 1 month, with 78% of patients maintaining satisfaction at 6 months post-treatment.

Intradermal HA and Skin Quality Biomarkers

The mechanism by which intradermal hyaluronic acid improves skin quality extends beyond simple hydration. When HA microdroplets integrate into the dermal matrix, they create a hydrated microenvironment that supports fibroblast activity, enhances collagen synthesis, and improves the organization of elastic fiber networks. Wang et al. (2007) showed that intradermal HA injection upregulates type I collagen gene expression by approximately 2-fold and stimulates fibroblast proliferation through CD44 receptor activation. This explains why SkinVive patients report not just improved hydration but also better skin texture, reduced fine lines, and enhanced elasticity — benefits that persist beyond the physical residence time of the injected HA because of the biological remodeling cascade initiated by the treatment. The controlled inflammatory response at each injection point also triggers growth factor release (TGF-beta, PDGF) that further promotes dermal matrix reorganization.

Clinical Evidence for SkinVive Efficacy and Safety

The clinical evidence supporting SkinVive is anchored in the SKIN trial (NCT05765097), a multicenter, randomized, controlled trial evaluating JUVÉDERM SKINVIVE for improvement of cheek skin quality. Results demonstrated that SkinVive treatment produced clinically meaningful and statistically significant improvements in skin smoothness as assessed by both clinicians and patients, with an excellent safety profile. Adverse events were primarily injection-site reactions (redness, swelling, bruising, tenderness) that resolved within 7 days in over 90% of patients. Importantly, no serious adverse events, vascular occlusion, or granuloma formation were reported, supporting the safety of the intradermal microdroplet injection technique when performed by trained physicians like those at RE:BERRY Myeongdong. Long-term follow-up showed SkinVive durability of up to 6 months — substantially longer than most competing skin booster products that require monthly maintenance sessions.

Niforos F et al. Dermatol Surg. 2023;49(Suppl 1):S22-S28. doi:10.1097/DSS.0000000000003710

Wang F et al. Arch Dermatol. 2007;143(2):155-163. doi:10.1001/archderm.143.2.155

Kerscher M et al. J Drugs Dermatol. 2017;16(4):317-323. doi:10.36849/JDD.2017.16.4.317